



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

FEB 2 1 1999  
FEB 24 1999

Norman H. Stepno  
Burns, Doane, Swecker & Mathis, L.L.P.  
P.O. Box 1404  
Alexandria, VA 22313-1404

In Re: Patent Term Extension  
Application for  
U.S. Patent No. Re. 34,440 (Sol'n)

## NOTICE OF FINAL DETERMINATION

A determination has been made that U.S. Patent No. Re. 34,440, which claims the method of use of the human drug product DIFFERIN Solution (adapalene), is eligible for patent term extension under 35 U.S.C. § 156. The period of extension has been determined to be 433 days.

The period of extension has been calculated using the FDA determination of the length of the regulatory review period published in the Federal Register of January 29, 1997 (62 Fed. Reg. 4300). Under 35 U.S.C. § 156(c):

$$\begin{aligned}\text{Period of Extension} &= \frac{1}{2} (\text{Testing Phase}) + \text{Approval Phase} \\ &= \frac{1}{2} (1,651 - 1,283) + 1,163 \\ &= 1,347 \text{ days}\end{aligned}$$

Since the regulatory review period began September 18, 1988, before the original patent issued (March 24, 1992), only that portion of the regulatory review period occurring after the date the patent issued has been considered in the above determination of the length of the extension period 35 U.S.C. § 156(c). (From September 18, 1988 to November 9, 1993 is 1,283 days; this period is subtracted from the number of days occurring in the testing phase according to the FDA determination of the length of the regulatory review period.) No determination of a lack of due diligence under 35 U.S.C. § 156(c)(1) was made.

However, the 14 year exception of 35 U.S.C. § 156(c)(3) operates to limit the term of the extension in the present situation because it provides that the period remaining in the term of the patent measured from the date of approval of the approved product plus any patent term extension cannot exceed fourteen years. The period of extension calculated above, 1,347 days, would extend the patent from March 24, 2009 to November 30, 2012, which is beyond the 14-year limit (14 years after the approval date is May 31, 2010). Accordingly, the period of extension is the number of days to extend the term of the patent from its original expiration date, March 24, 2009 to and including May 31, 2010, or 433 days.

The limitations of 35 U.S.C. § 156(g)(6) do not operate to further reduce the period of extension determined above.

Applicant has also filed applications for patent term extension of U.S. Patent Nos. Re. 34,440, 4,717,720, and 5,015,758, and 5,212,303 based upon the regulatory review of the product DIFFERIN Gel, and U.S. Patent Nos. 4,717,720, 5,015,758 and 5,212,303 based upon the regulatory review of the product DIFFERIN Solution. DIFFERIN Gel and DIFFERIN Solution have different regulatory review periods. No more than one patent may be extended based upon a regulatory review period of a product. 35 U.S.C. § 156(c)(4). A patent can only be extended once under 35 U.S.C. § 156(e)(1). 35 U.S.C. § 156(a)(2). When applications are filed for extension of the terms of different patents based upon the same regulatory review period for a product, the certificate of extension is issued to the patent having the earliest date of issuance unless applicant elects a different patent. Applicant is hereby **REQUIRED TO ELECT** a single patent for extension based upon the regulatory review period of DIFFERIN Solution. The same patent cannot also be elected for extension based upon the regulatory review of DIFFERIN Gel. In deciding which patent to elect, applicant should also consider that U.S. Patent Nos. 5,015,758 and 5,212,303 claim the method of manufacturing adapalene and, if either of these patents are elected, applicant would have the rights set forth in 35 U.S.C. 156(b)(3), but the extended expiration date will not be published in FDA's Orange Book. U.S. Patent No. Re. 34,440 claims the method of use of adapalene and, if elected, applicant would have the rights set forth in 35 U.S.C. 156(b)(2). U.S. Patent No. 4,717,720 claims adapalene and the method of use of adapalene and if elected, applicant would have the rights set forth in 35 U.S.C. 156(b)(1) and (2). If the above-identified patent is elected for extension based upon the regulatory review period of DIFFERIN Solution, the Commissioner will issue a certificate of extension, under seal, for a period of 433 days.

Upon issuance of the certificate of extension, the following information will be published in the Official Gazette:

U.S. Patent No.	:	Re. 34,440 (originally U.S. Patent No. 5,098,895)
Granted	:	November 9, 1993
Original Expiration Date	:	March 24, 2009
Applicant	:	Braham Shroot et al.
Owner of Record	:	Centre International de Recherches Dermatologiques
Title	:	Benzonaphthalene Derivatives, A Process of Their Preparation and Their Use in

Therapeutic and Cosmetic Compositions

Classification : 514/62  
Product Trade Name : DIFFERIN Topical Gel (adapalene)  
Term Extended : 433 days  
Expiration Date of Extension : May 31, 2010


Any correspondence from applicant with respect to this matter should be addressed as follows:

By mail: Assistant Commissioner for Patents  
Box Patent Ext.  
Washington, D.C. 20231

By FAX: (703) 308-6916  
Attn: Special Program Law Office

By hand: One Crystal Park, Suite 520  
2011 Crystal Drive  
Arlington, VA

Telephone inquiries related to this determination should be directed to the undersigned at (703) 306-3159.

  
Karin L. Tyson  
Senior Legal Advisor  
Special Program Law Office  
Office of the Deputy Assistant Commissioner  
for Patent Policy and Projects

cc: Ronald L. Wilson, Director  
Health Assessment Policy Staff  
Office of Health Affairs (HFY-20)  
Food and Drug Administration  
5600 Fishers Lane, Room 15-22  
Rockville, MD 20857

RE: DIFFERIN GEL  
FDA Docket No.: 96E-0362